ストックスクリーナーアプリを入手
31.27
1.12%
0.335
前日終値:
$30.93
開ける：
$31.01
24時間の取引高:
1.33M
Relative Volume:
0.65
時価総額：
$19.26B
収益：
$2.62B
当期純損益:
$966.70M
株価収益率:
20.84
EPS:
1.5004
ネットキャッシュフロー:
$1.09B
1週間 パフォーマンス:
-1.27%
1か月 パフォーマンス:
+7.63%
6か月 パフォーマンス:
+36.94%
1年 パフォーマンス:
+43.27%
1日の値動き範囲:
$30.81
$31.29
1週間の範囲:
$30.81
$32.41
52週間の値動き範囲:
$17.23
$33.65
Genmab Adr Stock (GMAB) Company Profile
GMAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
31.26 | 19.05B | 2.62B | 966.70M | 1.09B | 1.5004 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.31 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
721.89 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
891.70 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.56 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
191.96 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-23 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-04-01 | ダウングレード | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | 開始されました | Redburn Atlantic | Buy |
| 2024-09-04 | 再開されました | Morgan Stanley | Equal-Weight |
| 2024-08-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-15 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | ダウングレード | Citigroup | Neutral → Sell |
| 2023-12-06 | アップグレード | UBS | Neutral → Buy |
| 2023-11-10 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-11-08 | アップグレード | DNB Markets | Sell → Buy |
| 2023-10-18 | 開始されました | Exane BNP Paribas | Underperform |
| 2023-09-06 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | 開始されました | BTIG Research | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-31 | 開始されました | UBS | Neutral |
| 2023-05-12 | 開始されました | Morgan Stanley | Underweight |
| 2022-12-20 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-11-14 | 開始されました | William Blair | Mkt Perform |
| 2022-11-11 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2022-06-24 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-05-02 | 開始されました | Cowen | Market Perform |
| 2022-03-16 | アップグレード | UBS | Neutral → Buy |
| 2022-01-31 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-12-01 | 開始されました | Berenberg | Sell |
| 2021-09-16 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | 開始されました | Deutsche Bank | Buy |
| 2021-01-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | ダウングレード | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-06-25 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | 開始されました | Credit Suisse | Outperform |
| 2020-02-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-12-12 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2019-09-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-08-12 | 開始されました | Guggenheim | Buy |
| 2019-08-12 | 開始されました | Morgan Stanley | Overweight |
| 2019-08-12 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Genmab Adr (GMAB) 最新ニュース
Genmab A/S Sponsored ADR $GMAB Shares Bought by First Trust Advisors LP - Defense World
Quoin Pharm ADR Joins Rank Of Stocks With RS Ratings Over 90 - MSN
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) - GlobeNewswire Inc.
Marshall Wace LLP Cuts Stock Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Sold by American Century Companies Inc. - Defense World
AI Plays Lead Five Stocks To Watch Near Buy Points - Investor's Business Daily
Arrowstreet Capital Limited Partnership Raises Position in Genmab A/S Sponsored ADR $GMAB - Defense World
JPMorgan Chase & Co. Grows Stock Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
How Stock Of The Day Genmab Is Leveraging An $8 Billion Deal To Stoke Its Next Chapter - Investor's Business Daily
Genmab A/S Sponsored ADR $GMAB Position Reduced by Russell Investments Group Ltd. - MarketBeat
Capital Fund Management S.A. Has $4.68 Million Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Arbor Realty Trust Inc (ABR): What is the Risk Factor? - fostersleader.com
Level Four Advisory Services LLC Acquires 12,888 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Rockefeller Capital Management L.P. Purchases New Shares in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Purchased by Creative Planning - Defense World
AlphaCore Capital LLC Invests $44,000 in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S Sponsored ADR $GMAB Shares Sold by PNC Financial Services Group Inc. - MarketBeat
Genmab ADR Earns Membership In 95-Plus Composite Rating Club - MSN
AIMZ Investment Advisors LLC Has $3.43 Million Position in Genmab A/S Sponsored ADR $GMAB - Defense World
Stocks To Watch: Immunocore Holdings ADR Sees RS Rating Rise To 83 - MSN
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Vera Therapeutics Stock Earns RS Rating Upgrade - Investor's Business Daily
Q1 Earnings Estimate for Genmab A/S Issued By HC Wainwright - Defense World
Ocular Therapeutix Stock Earns 81 RS Rating - Investor's Business Daily
FY2025 EPS Estimates for Genmab A/S Raised by HC Wainwright - Defense World
Syndax Pharmaceuticals Stock Earns RS Rating Upgrade - Investor's Business Daily
Leerink Partnrs Forecasts Weaker Earnings for Genmab A/S - Defense World
Stocks With Rising Relative Strength: Immunocore Holdings ADR - Investor's Business Daily
FY2025 EPS Estimates for Genmab A/S Raised by William Blair - Defense World
Genmab A/S Sponsored ADR $GMAB Position Reduced by Y Intercept Hong Kong Ltd - Defense World
Genmab and BioNTech’s Promising Study on Metastatic Colorectal Cancer Treatment - MSN
eBay Upgraded, Meta Platforms Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Genmab A/S Sponsored ADR $GMAB Shares Sold by Ingalls & Snyder LLC - MarketBeat
William Blair Predicts Genmab A/S FY2027 Earnings - Defense World
Short Interest in Genmab A/S Sponsored ADR (NASDAQ:GMAB) Increases By 59.3% - MarketBeat
Bank of America Upgraded, Allstate Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Vanguard Personalized Indexing Management LLC Has $1.09 Million Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
HC Wainwright Has Pessimistic View of Genmab A/S Q2 Earnings - Defense World
Genmab A/S’s (GMAB) “Buy” Rating Reiterated at HC Wainwright - Defense World
Genmab Adr (GMAB) 財務データ
収益
当期純利益
現金流量
EPS
0.80%
0.04%
大文字化:
|
ボリューム (24 時間):